iPSC0028 MAPT P301S 1B9C9
SIGi001-A-6
General#
Cell Line |
|
| hPSCreg Name | SIGi001-A-6 |
| Alternative name(s) |
iPSC0028 MAPT P301S 1B9C9
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 7th August 2019 |
| Notes | The parental iPSC line SIGi001-A can be sourced via Sigma as 'iPSC0028'. |
| User feedback | |
Provider |
|
| Generator | Sigma-Aldrich (SIG) |
| Owner | Janssen Pharmaceutica (JP) |
| Distributors | |
External Databases |
|
| BioSamples | SAMEA4447426 |
| Cellosaurus | CVCL_EF87 |
| ECACC | 66540326 |
| EBiSC | SIGi001-A-6 |
| CLO | CLO_0102740 |
| Wikidata | Q54953463 |
General Information |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research: allowed
Clinical: allowed
Commercial: allowed
|
| Subclone of | |
Donor Information#
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | no |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA4447434 |
Ethics#
Also have a look at the ethics information for the parental line
SIGi001-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation#
General |
|
|
The source cell information can be found in the parental cell line
SIGi001-A.
|
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SSEA-1 |
No |
|
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| GATA6 |
Yes |
| TBX5 |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| PAX6 |
Yes |
| NeuroD |
Yes |
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
31
|
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755 This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768 |
Genetic Modification#
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.